A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Annals of Oncology

Volumn 26, Issue 12, 2015, Pages 2483-2490

  Nowak, A K ^a,b,c   Cook, A M ^b,c   McDonnell, A M ^b,c   Millward, M J ^a,b   Creaney, J ^b,c   Francis, R J ^a,b,c   Hasani, A ^a   Segal, A ^a   Musk, A W ^a,b,c   Turlach, B A ^c   McCoy, M J ^b,d   Robinson, B W S ^a,b,c   Lake, R A ^b,c  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ST JOHN OF GOD HOSPITAL   (Australia)

Author keywords

CD40; Clinical trial; Immunotherapy; Malignant mesothelioma; Phase I

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CP 870893; PEMETREXED; ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CP-870,893; MONOCLONAL ANTIBODY;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; CYTOKINE RELEASE SYNDROME; DOSE RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HYPONATREMIA; LIVER VEIN THROMBOSIS; MALE; MEMORY CELL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SPLEEN INFARCTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADULT; AGED; AGONISTS; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PLEURAL NEOPLASMS; PROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PEMETREXED; PLEURAL NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84949936992     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv387     Document Type: Article

References (16)

1. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63: 4490-4496.
2. Vonderheide RH, Burg JM, Mick R et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2: e23033.
3. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13: 1083-1088.
4. Ruter J, Antonia SJ, Burris HA et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther 2010; 10: 983-993.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
6. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889.
7. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.
8. Francis RJ, Byrne MJ, van der Schaaf AA et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007; 48: 1449-1458.
9. Nowak AK, Millward MJ, Creaney J et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 1449-1456.
10. Beatty GL, Torigian DA, Chiorean EG et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013; 19: 6286-6295.
11. Damas JK, Otterdal K, Yndestad A et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 2004; 110: 999-1005.
12. Vonderheide RH, Flaherty KT, Khalil M et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25: 876-883.
13. Robbins PF, Lu YC, El-Gamil M et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19: 747-752.
14. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005; 238: 67-75.
15. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol 2013; 131: 959-971.
16. Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med 2009; 7: 93.